A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2)
18 Years and older, Male and Female
ALKS 4230-001 (primary)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
This study will evaluate ALKS 4230 administered SC as lead-in monotherapy and in combination
with pembrolizumab in subjects with advanced solid tumors.